SCA
VYNE icon

STALEY CAPITAL ADVISERS’s VYNE Therapeutics VYNE Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.8K Hold
51,472
– – ﹤0.01% 182
2025
Q4 		$29.9K Hold
51,472
– – ﹤0.01% 192
2025
Q3 		$17.2K Hold
51,472
– – ﹤0.01% 197
2025
Q2 		$84.9K Hold
51,472
– – ﹤0.01% 189
2025
Q1 		$81.3K Buy
51,472
+15,000
+41% +$36.9K ﹤0.01% 185
2024
Q4 		$122K Hold
36,472
– – 0.01% 173
2024
Q3 		$68.6K Hold
36,472
– – ﹤0.01% 180
2024
Q2 		$71.8K Hold
36,472
– – ﹤0.01% 177
2024
Q1 		$112K Hold
36,472
– – 0.01% 177
2023
Q4 		$85K Buy
36,472
+13,000
+55% +$40.5K ﹤0.01% 176
2023
Q3 		$94.8K Hold
23,472
– – 0.01% 171
2023
Q2 		$96.2K Hold
23,472
– – 0.01% 180
2023
Q1 		$72K Buy
23,472
+20,000
+576% +$71.8K ﹤0.01% 174
2022
Q4 		$9K Hold
3,472
– – ﹤0.01% 166
2022
Q3 		$14K Hold
3,472
– – ﹤0.01% 167
2022
Q2 		$24K Hold
3,472
– – ﹤0.01% 167
2022
Q1 		$41K Hold
3,472
– – ﹤0.01% 178
2021
Q4 		$64K Buy
3,472
+694
+25% +$14.9K ﹤0.01% 187
2021
Q3 		$70K Buy
2,778
+695
+33% +$27K ﹤0.01% 180
2021
Q2 		$132K Buy
2,083
+694
+50% +$54.9K 0.01% 177
2021
Q1 		$171K Buy
1,389
+695
+100% +$101K 0.01% 178
2020
Q4 		$79K Buy
+694
New +$87.2K ﹤0.01% 178

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

STALEY CAPITAL ADVISERS's VYNE Position: Q1 2026 in Review

STALEY CAPITAL ADVISERS held its VYNE Therapeutics (VYNE) position steady in Q1 2026 at 51,472 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #182.

STALEY CAPITAL ADVISERS first reported a position in VYNE in Q4 2020 and has held it in 22 quarters since. The position peaked at $171K in Q1 2021. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • STALEY CAPITAL ADVISERS held 51,472 shares of VYNE Therapeutics worth $30.8K as of Q1 2026.
  • STALEY CAPITAL ADVISERS left its VYNE Therapeutics share count unchanged in Q1 2026.
  • VYNE Therapeutics made up ﹤0.01% of STALEY CAPITAL ADVISERS's portfolio in Q1 2026, its #182 holding.
  • STALEY CAPITAL ADVISERS first reported a position in VYNE Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • STALEY CAPITAL ADVISERS's VYNE Therapeutics position peaked at $171K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q1 2026, filed 29 Apr 2026.